Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]

This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The art...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Stanley B, Leach, Mariah Z
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2023
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625413/
https://www.ncbi.nlm.nih.gov/pubmed/37927492
http://dx.doi.org/10.2147/OARRR.S443235
_version_ 1785131128385961984
author Cohen, Stanley B
Leach, Mariah Z
author_facet Cohen, Stanley B
Leach, Mariah Z
author_sort Cohen, Stanley B
collection PubMed
description This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis.
format Online
Article
Text
id pubmed-10625413
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-106254132023-11-05 Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast] Cohen, Stanley B Leach, Mariah Z Open Access Rheumatol Commentary This article discusses some of the queries and concerns that patients may have about initiating or switching to treatment with a biosimilar for rheumatoid arthritis following the US 2023 release of several biosimilars of the adalimumab reference product, also known by the brand name, Humira. The article also covers the difference between a generic medicine and a biosimilar, and the clinical evidence to support the safety and efficacy of adalimumab biosimilars in patients with rheumatoid arthritis. Dove 2023-10-31 /pmc/articles/PMC10625413/ /pubmed/37927492 http://dx.doi.org/10.2147/OARRR.S443235 Text en © 2023 Boehringer Ingelheim Pharmaceuticals, Inc. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Commentary
Cohen, Stanley B
Leach, Mariah Z
Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
title Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
title_full Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
title_fullStr Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
title_full_unstemmed Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
title_short Biosimilars for Rheumatoid Arthritis: Riding the 2023 Wave [Podcast]
title_sort biosimilars for rheumatoid arthritis: riding the 2023 wave [podcast]
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625413/
https://www.ncbi.nlm.nih.gov/pubmed/37927492
http://dx.doi.org/10.2147/OARRR.S443235
work_keys_str_mv AT cohenstanleyb biosimilarsforrheumatoidarthritisridingthe2023wavepodcast
AT leachmariahz biosimilarsforrheumatoidarthritisridingthe2023wavepodcast

Ejemplares similares